MedTrace Logo

Urolithin A Supplementation to Boost Immune Health

NCT05735886 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-09-26

No results posted yet for this study

Summary

To show that a natural mitophagy activator (Urolithin A) given orally can modulate mitochondrial activity in immune cells in healthy adults and this results in better immune function

Conditions

  • Aging

Interventions

DIETARY_SUPPLEMENT

Softgel containing placebo

Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days

DIETARY_SUPPLEMENT

Softgel containing 250mg of Urolithin A (Mitopure)

Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days

Sponsors & Collaborators

  • Goethe University

    collaborator OTHER

  • Amazentis SA

    lead INDUSTRY

Principal Investigators

  • Dr. Dominic Denk, MD · Universitätsklinikum Frankfurt Medizinische Klinik I

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2024-03-31
Completion
2024-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05735886 on ClinicalTrials.gov